The company announced on October 10 that its Unit 4 in Jadcherla, Telangana, passed an inspection by AGES Austria from July 27 to July 30, 2026, and received GMP certification.
According to the regulatory filing, the unit produces sterile injections and non‑sterile tablets and capsules, products already distributed to Europe and other global markets. The certification is expected to remove a key regulatory hurdle, potentially accelerating sales growth in the EU.
In parallel, Shilpa Medicare secured final approval from the Central Drugs Standard Control Organization for its extended‑release ondansetron injection, OERIS, after a successful Phase III trial. The product, protected by a patent until 2039, is slated for commercial launch across India this quarter, adding a new revenue stream.
The stock reaction was muted: shares closed at ₹1,025.70, up ₹0.40 or 0.04% on the NSE, reflecting a cautious but optimistic stance from traders. Analysts noted that the certification and OERIS approval could lift the company’s average revenue per employee, a metric that has trended upward over the last two fiscal years.
Looking ahead, management highlighted that the new certification will enable the company to bid for large European contracts, while the OERIS launch is expected to drive a 12‑15% revenue lift in FY27Q2. Investors will be watching the next earnings call on December 5 for detailed guidance on international expansion and product pipeline performance.